NxStage Medical (NXTM) Lifted to “Buy” at Zacks Investment Research

NxStage Medical (NASDAQ:NXTM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. The firm currently has a $33.00 price target on the medical device company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 13.13% from the company’s current price.

According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “

Separately, BidaskClub upgraded shares of NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, December 21st.

NASDAQ:NXTM opened at $29.17 on Thursday. NxStage Medical has a 12 month low of $22.87 and a 12 month high of $29.33. The stock has a market capitalization of $1.94 billion, a PE ratio of -132.59 and a beta of 0.25.

Several institutional investors have recently modified their holdings of the stock. American International Group Inc. increased its stake in shares of NxStage Medical by 0.9% in the 4th quarter. American International Group Inc. now owns 43,417 shares of the medical device company’s stock worth $1,243,000 after acquiring an additional 393 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of NxStage Medical by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 830,123 shares of the medical device company’s stock worth $23,758,000 after acquiring an additional 31,469 shares in the last quarter. ARP Americas LP increased its stake in shares of NxStage Medical by 80.4% in the 4th quarter. ARP Americas LP now owns 160,135 shares of the medical device company’s stock worth $4,583,000 after acquiring an additional 71,366 shares in the last quarter. PEAK6 Investments LLC increased its stake in shares of NxStage Medical by 47.1% in the 4th quarter. PEAK6 Investments LLC now owns 70,900 shares of the medical device company’s stock worth $2,029,000 after acquiring an additional 22,700 shares in the last quarter. Finally, Murphy Pohlad Asset Management LLC bought a new position in shares of NxStage Medical in the 4th quarter worth about $28,000. Institutional investors own 81.28% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Further Reading: Why does a company issue an IPO?

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply